Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-09-09
DOI
https://doi.org/10.1200/jco-24-01544
Citations
144
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
60.33

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Federico Cappuzzo, Gee-Chen Chang, Kadoaki Ohashi, Satoshi Sakaguchi et al.
144 citations
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
60.33
article

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Federico Cappuzzo, Gee-Chen Chang, Kadoaki Ohashi, Satoshi Sakaguchi, Filippo de Marinis, Chee‐Seng Tan, Shun Lü, Ki Hyeong Lee, Ryo Ko, Benjamin Shieh, Óscar Juan, Yuichi Tambo, Elvire Pons‐Tostivint, Byoung Yong Shim, Min Hee Hong, Francisco Javier Ramírez Godinez, Masashi Kondo, Gaëtan Catala, Rodryg Ramlau, Paul Howarth, Akin Atmaca, Fabio M. Gomes, Céline Mascaux, Juergen Wolf, Michael Chargualaf, Manuel Cobo, Naveen S. Basappa, Е. V. Ledin, Yu‐Feng Wei, Froylán López-López, Jaafar Bennouna, T. Mansy, Denis Moro‐Sibilot, Mirelis Acosta-Rivera, Stefania Salvagni, Robert Mróz, Hiroshi Tanaka, Claudia Proto, Yasushi Goto, Myung‐Ju Ahn, Yu Yao, Motohiro Tamiya, Ferdinando Cerciello, Hidetoshi Hayashi, H. Léna, W.C. Chang, M. Pérol, Satoshi Oizumi, Benjamin Solomon, Sang‐We Kim, Sebahat Ocak, Héctor Soto Parrà, Tsung‐Ying Yang, Melissa L. Johnson, Robin Cornelissen, Luis Paz‐Ares, Kiyotaka Yoh, Elena Poddubskaya, Jacob M. Sands, Julien Mazières, Satoru Kitazono, Margarita Majem, Daniel Brungs, Takayasu Kurata, Laurent Greillier, Bruno Fang, Jerónimo Rafael Rodríguez Cid, Sujith Kalmadi, Christos S. Karapetis, Deise Uema, Dariusz M. Kowalski, Niels Reinmuth, Richard D. Hall, José Fuentes Pradera, Toshiyuki Kozuki, Christian Schumann, Hideaki Mizutani, Aaron Elliott Lisberg, Haruko Daga, Dolores Isla, Manuel Dómine, Shunichi Sugawara, Balázs Halmos, Mariano Provencio, Christine Greil, Andrea Veatch, Anna Łowczak, Tirrell Johnson, Sagun Parakh, Gastón Lucas Martinengo, Noemı́ Reguart, Cheol Park, Csaba Böcskei, Ines B. Menjak, Milada Zemanová, Enriqueta Felip, Nicolas M Girard, Jos A. Stigt, Marina Chiara Garassino, Adnan Nagria, Yong Zhang, Janusz Milanowski, Jin-Soo Kim, Jialei Wang, Geoffrey Liu, Jin-Hyoung Kang, Kentaro Tanaka, Hongmei Sun, Se Hyun Kim, Amit Jain, Bo Gao, Ahad A. Sadiq, Virginie Westeel, Corinne Lamour, Martin Früh, Wen-Tsung Huang, Thomas Wehler, Tanya Ahmad, Steven Gans, Boon Yeow Daniel Chan, James Ho, Yee Soo Chae, Feng Luo, Silvia Novello, Chien-Chung Ling, Frédéric Forget, Manlio Mencoboni, Maria Carmen Areses, William Lawler, H Ozasa, Juan Puig, Yun Gyoo Lee, Débora S. Bruno, David Vicente Baz, Khawaja Jahangir, Michael Castine
article en
144 citations

Abstract

Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.

Journal of Clinical OncologyVol. 43(3)
Universitat Autònoma de Barcelona (ES), University of California, Los Angeles (US), Shanghai Jiao Tong University (CN), University of Wollongong (AU), University of Virginia Health System (US), Severance Hospital (KR), Samsung Medical Center (KR), Shanghai Chest Hospital (CN), Hospital Universitari i Politècnic La Fe (ES), Centre Hospitalier Universitaire de Nantes (FR), University of Chicago (US), Hospital Universitario Virgen Macarena (ES), Kindai University Hospital (JP), Kyushu University Hospital (JP), Hospital Universitario 12 De Octubre (ES), Centre Léon Bérard (FR), Dana-Farber Cancer Institute (US), The Cancer Institute Hospital (JP), Hôpitaux Universitaires de Strasbourg (FR), Erasmus MC Cancer Institute (NL), Daiichi Sankyo (United States) (US), Instituto de Investigación Biomédica de Málaga (ES), Sendai Kousei Hospital (JP), Japanese Foundation For Cancer Research (JP), Institut Curie (FR), Sungkyunkwan University (KR)
Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 0%
Lung Cancer Treatments and Mutations
60.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.